Cargando…
Cross neutralization of SARS‐CoV‐2 omicron subvariants after repeated doses of COVID‐19 mRNA vaccines
We have measured the humoral response to messenger RNA (mRNA) vaccines in COVID‐19 naïve and convalescent individuals. Third doses of mRNA COVID‐19 vaccines induced a significant increase in potency and breadth of neutralization against SARS‐CoV‐2 variants of concern (VoC) including Omicron subvaria...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828064/ https://www.ncbi.nlm.nih.gov/pubmed/36319593 http://dx.doi.org/10.1002/jmv.28268 |
_version_ | 1784867186402131968 |
---|---|
author | Luczkowiak, Joanna Rivas, Gonzalo Labiod, Nuria Lasala, Fátima Rolo, Marta Lora‐Tamayo, Jaime Mancheno‐Losa, Mikel Rial‐Crestelo, David Pérez‐Rivilla, Alfredo Folgueira, María Dolores Delgado, Rafael |
author_facet | Luczkowiak, Joanna Rivas, Gonzalo Labiod, Nuria Lasala, Fátima Rolo, Marta Lora‐Tamayo, Jaime Mancheno‐Losa, Mikel Rial‐Crestelo, David Pérez‐Rivilla, Alfredo Folgueira, María Dolores Delgado, Rafael |
author_sort | Luczkowiak, Joanna |
collection | PubMed |
description | We have measured the humoral response to messenger RNA (mRNA) vaccines in COVID‐19 naïve and convalescent individuals. Third doses of mRNA COVID‐19 vaccines induced a significant increase in potency and breadth of neutralization against SARS‐CoV‐2 variants of concern (VoC) including Omicron subvariants BA.1, BA.2, and BA.2.12.1, that were cross‐neutralized at comparable levels and less for BA.4/5. This booster effect was especially important in naïve individuals that only after the third dose achieved a level that was comparable with that of vaccinated COVID‐19 convalescents except for BA.4/5. Avidity of RBD‐binding antibodies was also significantly increased in naïve individuals after the third dose, indicating an association between affinity maturation and cross neutralization of VoC. These results suggest that at least three antigenic stimuli by infection or vaccination with ancestral SARS‐CoV‐2 sequences are required to induce high avidity cross‐neutralizing antibodies. Nevertheless, the circulation of new subvariants such as BA.4/5 with partial resistance to neutralization will have to be closely monitored and eventually consider for future vaccine developments. |
format | Online Article Text |
id | pubmed-9828064 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98280642023-01-10 Cross neutralization of SARS‐CoV‐2 omicron subvariants after repeated doses of COVID‐19 mRNA vaccines Luczkowiak, Joanna Rivas, Gonzalo Labiod, Nuria Lasala, Fátima Rolo, Marta Lora‐Tamayo, Jaime Mancheno‐Losa, Mikel Rial‐Crestelo, David Pérez‐Rivilla, Alfredo Folgueira, María Dolores Delgado, Rafael J Med Virol Short Communications We have measured the humoral response to messenger RNA (mRNA) vaccines in COVID‐19 naïve and convalescent individuals. Third doses of mRNA COVID‐19 vaccines induced a significant increase in potency and breadth of neutralization against SARS‐CoV‐2 variants of concern (VoC) including Omicron subvariants BA.1, BA.2, and BA.2.12.1, that were cross‐neutralized at comparable levels and less for BA.4/5. This booster effect was especially important in naïve individuals that only after the third dose achieved a level that was comparable with that of vaccinated COVID‐19 convalescents except for BA.4/5. Avidity of RBD‐binding antibodies was also significantly increased in naïve individuals after the third dose, indicating an association between affinity maturation and cross neutralization of VoC. These results suggest that at least three antigenic stimuli by infection or vaccination with ancestral SARS‐CoV‐2 sequences are required to induce high avidity cross‐neutralizing antibodies. Nevertheless, the circulation of new subvariants such as BA.4/5 with partial resistance to neutralization will have to be closely monitored and eventually consider for future vaccine developments. John Wiley and Sons Inc. 2022-11-10 2023-01 /pmc/articles/PMC9828064/ /pubmed/36319593 http://dx.doi.org/10.1002/jmv.28268 Text en © 2022 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Short Communications Luczkowiak, Joanna Rivas, Gonzalo Labiod, Nuria Lasala, Fátima Rolo, Marta Lora‐Tamayo, Jaime Mancheno‐Losa, Mikel Rial‐Crestelo, David Pérez‐Rivilla, Alfredo Folgueira, María Dolores Delgado, Rafael Cross neutralization of SARS‐CoV‐2 omicron subvariants after repeated doses of COVID‐19 mRNA vaccines |
title | Cross neutralization of SARS‐CoV‐2 omicron subvariants after repeated doses of COVID‐19 mRNA vaccines |
title_full | Cross neutralization of SARS‐CoV‐2 omicron subvariants after repeated doses of COVID‐19 mRNA vaccines |
title_fullStr | Cross neutralization of SARS‐CoV‐2 omicron subvariants after repeated doses of COVID‐19 mRNA vaccines |
title_full_unstemmed | Cross neutralization of SARS‐CoV‐2 omicron subvariants after repeated doses of COVID‐19 mRNA vaccines |
title_short | Cross neutralization of SARS‐CoV‐2 omicron subvariants after repeated doses of COVID‐19 mRNA vaccines |
title_sort | cross neutralization of sars‐cov‐2 omicron subvariants after repeated doses of covid‐19 mrna vaccines |
topic | Short Communications |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828064/ https://www.ncbi.nlm.nih.gov/pubmed/36319593 http://dx.doi.org/10.1002/jmv.28268 |
work_keys_str_mv | AT luczkowiakjoanna crossneutralizationofsarscov2omicronsubvariantsafterrepeateddosesofcovid19mrnavaccines AT rivasgonzalo crossneutralizationofsarscov2omicronsubvariantsafterrepeateddosesofcovid19mrnavaccines AT labiodnuria crossneutralizationofsarscov2omicronsubvariantsafterrepeateddosesofcovid19mrnavaccines AT lasalafatima crossneutralizationofsarscov2omicronsubvariantsafterrepeateddosesofcovid19mrnavaccines AT rolomarta crossneutralizationofsarscov2omicronsubvariantsafterrepeateddosesofcovid19mrnavaccines AT loratamayojaime crossneutralizationofsarscov2omicronsubvariantsafterrepeateddosesofcovid19mrnavaccines AT manchenolosamikel crossneutralizationofsarscov2omicronsubvariantsafterrepeateddosesofcovid19mrnavaccines AT rialcrestelodavid crossneutralizationofsarscov2omicronsubvariantsafterrepeateddosesofcovid19mrnavaccines AT perezrivillaalfredo crossneutralizationofsarscov2omicronsubvariantsafterrepeateddosesofcovid19mrnavaccines AT folgueiramariadolores crossneutralizationofsarscov2omicronsubvariantsafterrepeateddosesofcovid19mrnavaccines AT delgadorafael crossneutralizationofsarscov2omicronsubvariantsafterrepeateddosesofcovid19mrnavaccines |